Prof. Dr. Mehmet Hilmi Dogu

Prof. Dr. Mehmet Hilmi Dogu
Academic Title :
Prof. Dr.

Prof. Dr. Mehmet Hilmi Doğu is a hematologist practicing at Liv Hospital Ulus and Liv Hospital Bahçeşehir in Istanbul, Turkey, as listed by the hospital in 2026. He graduated from Ege University Faculty of Medicine in 2005, completed his internal medicine specialization at Pamukkale University in 2011, and qualified as a hematologist in 2014. He became an Associate Professor in 2018 and a Professor in 2023. His principal clinical interests include chronic leukemia, Hodgkin and non-Hodgkin lymphoma, multiple myeloma, and chronic myeloproliferative disorders. He has contributed to clinical research in hematologic malignancies, stem cell transplantation, and therapeutic apheresis and maintains an academic affiliation with İstinye University.

Education and Academic Qualifications

  • 1999–2005: Medical degree, Ege University Faculty of Medicine, Turkey.

  • 2006–2011: Internal Medicine specialization, Pamukkale University, Turkey.

  • 2011–2014: Hematology subspecialty training, Pamukkale University, Turkey.

  • May 2014: ESCCA Summer School on Cytometry, Prague.

  • 2018: Awarded the title of Associate Professor in Hematology.

  • 2023: Awarded the title of Professor, as documented by the Turkish Society for Apheresis.

Areas of Interest

  • Chronic lymphocytic leukemia (CLL) diagnosis and treatment in Turkey.

  • Chronic myeloid leukemia (CML) management.

  • Hodgkin and non-Hodgkin lymphoma.

  • Multiple myeloma and plasma cell disorders.

  • Chronic myeloproliferative neoplasms.

  • Polycythemia vera.

  • Essential thrombocythemia.

  • Myelofibrosis.

  • Hematologic malignancy evaluation and follow-up.

  • Hematologic assessment of candidates for hematopoietic stem cell transplantation.

  • Anemia, platelet disorders, and abnormal blood count evaluation.

  • Medical Doctor at Saraykoy State Hospital in Denizli (2011)
  • Hematology Specialist at Selcuk University Hospital (2015)
  • Hematology Specialist at Istanbul Training and Research Hospital Hematology Clinic (2015 - 2020)
  • Administrative Director at Istanbul Training and Research Hospital Hematology Clinic (2015 - 2020)
  • Hematology Specialist at Basaksehir Cam and Sakura City Hospital in Istanbul (2020)
  • Professor and Hematology Specialist at Liv Hospital Ulus and Liv Hospital Bahcesehir (2021 - Present)
  • Member of the Turkish Society of Hematology
  • Board Member of the Society of Hematological Education and Research
  • Karışmaz A, Çavdar VC, Doğu MH, et al. Evaluation of The Relationship Between Bone Marrow Changes and Hemogram Findings in HIV-Positive Patients. Namık Kemal Medical Journal. 2025;13(1):76–86. DOI: 10.4274/nkmj.galenos.2025.29494.

  • Kayıkçı Ö, Mehtap Ö, Sarı İ, et al., including Doğu MH. Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). Turkish Journal of Hematology. 2022. PMID: 35678126.

  • Doğu MH, Nizam N, Eren R, Suyani E. Is It Brucellosis or Multiple Myeloma? Or Can It Be Both? Journal of Hematology & Multiple Myeloma. 2016;1:1–3.

  • Hacıoğlu S, Sarı İ, Doğu MH, Keskin A. The Effect of Gradual Increment in rhG-CSF Dose on Stem Cell Yields in Patients with Multiple Myeloma Mobilized with Intermediate Dose Cyclophosphamide Plus rhG-CSF. Transfusion and Apheresis Science. 2014;50(1):71–74. DOI: 10.1016/j.transci.2013.11.003.

  • Tombak A, et al., including Doğu MH. The Role of Azacitidine in the Treatment of Elderly Patients with AML—Results of a Retrospective Multicenter Study. Turkish Journal of Hematology. 2016. DOI: 10.4274/tjh.2015.0203.

  • Hacıoğlu S, et al., including Doğu MH. Multicenter Retrospective Analysis Regarding the Clinical Manifestations and Treatment Results in Patients with Hairy Cell Leukemia: Twenty-Four Year Turkish Experience in Cladribine Therapy. Hematological Oncology. 2015;33(4):192–198. DOI: 10.1002/hon.2177.

Share :